U.S. Markets open in 8 hrs 25 mins

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
22.51-0.10 (-0.44%)
At close: 4:00PM EDT
People also watch
  • A rare gem

    Cory Renauer (Omeros Corporation): This biotech has a rare disease drug in development that could render its stock chart into the shape of a hockey stick. The candidate, tentatively named OMS721, throws a wrench in the works of a complex series of steps that can lead to the uncontrolled destruction of tiny blood vessels. The normal function of this component of the immune system removes foreign particles. Among a small group of patients with rare genetic conditions, though, uncontrolled activation of the complement system leads to life threatening clots within tiny blood vessels throughout the body.
    There is a treatment available for one of these genetic conditions, atypical hemolytic uremic syndrome (aHUS), called Soliris from Alexion Pharmaceuticals. Unfortunately for aHUS patients it often causes headaches, diarrhea, and has been known to increase the risk of dangerous infections. Despite Soliris' drawbacks, it raked in a stunning $2.6 billion last year, and it stands to reason that a more tolerable treatment for inherited complement system disorders could top this figure.

    Omeros Corporation's stock price has more than doubled this year, as the company dropped hints an ongoing clinical trial with aHUS patients designed to support an FDA application could succeed. A relative lack of side effects compared to Soliris could make a potential new drug launch incredibly successful, provided it earns FDA approval. If OMS721 becomes half as successful as Soliris, this company's market cap of just $965 million would probably swell to several times its current size.
    Perhaps my favorite feature of this biotech is that it already has a growing source of revenue to fund OMS721's clinical trials. The company markets a pupil dilator called Omidria, and it's becoming increasingly popular among eye surgeons that perform millions of cataract removals and lens replacement surgeries each year. Omidria's ability to reduce complications has sent its sales surging to a level could make Omeros a profitable company this year, which could limit losses if an unexpected snafu causes OMS721 to fizzle.
  • We are getting close now to the EU announcement. Just based on the cash portion of the deal it values the company at $5.0billion or around $110 per share. The quarter will be better than expected as there was a catch on revenues based on improper wholesaling issues. 721 is getting closer at the FDA but not quite there. Before the end of Sept. And believe it or not there is another drug that is anti addition that has huge potential that is being moved along very fast. I will be hard to put a value on all of this. The short story is over with the last failed attempt. No buyout just massive sales, and partnerships.
  • The fool article did not move the stock. Chart technicals look like they are rolling over.

    I think the stock is going to base for a bit before it moves up again. Maybe a week or two.
  • Report: MASP-2 (target for OMS7221) associated with ischemic stroke and contribution to post-stroke brain damage:

    J Clin Pathol. 2017 Jul 18. pii: jclinpath-2017-204403. doi: 10.1136/jclinpath-2017-204403. [Epub ahead of print]
    Serine proteases of the complement lectin pathway and their genetic variations in ischaemic stroke.
    Tsakanova G1, Stepanyan A1, Nahapetyan K2, Sim RB3,4, Arakelyan A1, Boyajyan A1.
    Author information

    The aim of the current study was to assess the proteolytic activities of collectin-bound MASP-1 and MASP-2 in the blood of patients with ischaemic stroke, as well as the association of their six genetic polymorphisms (rs3203210, rs28945070, rs28945073 in MASP1 gene and rs2273343, rs12711521, rs147270785 in MASP2 gene) with this pathology.
    In total, 250 patients and 300 healthy subjects were involved in this study. MBL-associated serine protease (MASP)-1 and MASP-2 activities were measured using in-house developed immunofluorescent and enzyme-linked immunosorbent assays, respectively. Sequence specific primer PCR was used to study the association of MASP1 and MASP2 genetic polymorphisms with ischaemic stroke.
    The results obtained demonstrate that the activities of collectin-bound MASP-1 and MASP-2 in patients with ischaemic stroke are significantly higher than those in healthy subjects (p<0.001). According to the data obtained for genotyping, the rs3203210 polymorphism in the MASP1 gene and the rs147270785 polymorphism in the MASP2 gene are associated with ischaemic stroke (p<0.0001).
    In conclusion we suggest that the complement lectin pathway serine proteases, MASP-1 and MASP-2, can be associated with ischaemic stroke development risk and may participate in pathological events leading to post-ischaemic brain damage. Moreover rs3203210 and rs147270785 single nucleotide polymorphisms in the MASP1 and MASP2 genes, respectively, are strongly associated with ischaemic stroke, and the minor rs3203210*C and rs147270785*A alleles of these polymorphisms may be considered as protective factors for ischameic stroke, at least in the Armenian population.


  • Omer will go to $30 soon
  • A foreign cash repatriation holiday would be great for small caps too by freeing up partnership cash from bigger fish. Too bad tiny hands long ties covering tiny shvantz can't stop losing.
  • OT-Billy
    What do you think is up with AKAO?
    Sorry for the intrusion OMER board members ... just wanted to get Billy's opinion and I know he reads here more than there.
    Have a good one!

    Higher highs, higher lows ... carry on!!


  • Relax🌴😎
  • Thanks GreatDayGuru on your previous post a couple of days ago I just bought ACRX at the low ONLY 2 days ago. it is for real....my guess is a quick 5x pps VERY short term and they are the REAL DEAL!! I think the majority of us on here would have to agree that OMER is going to break out. I agree and LONG on ACRX and OMER!!!!
  • ACRX (up 10%) and OMER (up over 3%)! Dr. Palmer co-founder of both... Last week HC Wainwright gave ACRX a Buy Recommendation = 280% upside... Go Omeros, over 20% Short Interest scrambling on what to do...
  • Encouraging run up to the close
  • Fool article will pop this buy a dollar today.
  • Updated short interest, 7/14/2017 8,996,193 824,183 10.915286
    6/30/2017 8,262,474 2,324,700 3.554211
  • Shorts on this message board meet at the overlap in a Venn diagram with circles of stupid, stubborn and trolly
  • I think we may go lower soon. Not much, but maybe mid $21s.
  • Would be incredible to hit 23 and stay there at EOD. A man can only dream 😃
  • We are holding 22 today
  • Very interesting. XBI is down and omer is up. If this holds I think it is possible that shore covering has begun.
  • i guess the news has leaked out